
nRichDX® Launches CTC Enrichment Kit on Revolution Sample Prep System
nRichDX®, a cancer diagnostics company, has unveiled a new research tool for liquid biopsy assays. The new Revolution CTC Enrichment Kit (Epithelial Origin)™ is used in the isolation of Circulating Tumor Cells (CTCs) from larger blood samples. Circulating Tumor Cells (CTCs) are a critical component of liquid biopsy assays, providing valuable insights into the presence and progression of cancer within the body. These cells are known to be indicative of aggressive cancers that have metastasized, spreading to other parts of the body. nRichDX’s new Revolution CTC Enrichment Kit (Epithelial Origin)™ is designed to work seamlessly with the Revolution Sample Prep System™ and can isolate CTCs from up to 40mL of whole blood samples. This extended capacity allows researchers to extract more comprehensive data from a single blood sample. The kit complements other Revolution Kits™ within the Revolution Sample Prep System™, enabling the concurrent enrichment and purification of CTCs, circulating cell-free DNA (cfDNA), and circulating cell-free total nucleic acid (cfTNA), including cfRNA, all from the same blood sample. This holistic approach provides the ability to assess various cancer markers in a single, convenient blood sample.
The Revolution CTC Enrichment Kit (Epithelial Cell Origin)™ employs immunomagnetic enrichment with antibodies targeting cellular markers like Epithelial Cell Adhesion Molecule (EpCAM). This ensures the isolation of a higher number of CTCs while reducing non-relevant artifacts. Future iterations of nRichDX CTC enrichment kits will focus on specific CTC cancer markers tailored to different cancer types. Data showcasing the efficacy of the new CTC enrichment kit were recently presented at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting. The poster presentation, titled “Extraction of Multiple Analytes in Liquid Biopsy May Improve the Diagnosis of Breast Cancer,” highlighted the kit’s ability to extract multiple analytes from blood samples, providing a more comprehensive cancer marker assessment. In the study 88% of spike circulating tumor cells were recovered utilizing the Revolution CTC Enrichment Kit. The study demonstrated the ability to provide an optimized extraction method of cfTNA and CTCs from a single blood sample.